Cite
Adcitmer®, a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma*.
MLA
Esnault, C., et al. “Adcitmer®, a New CD56‐targeting Monomethyl Auristatin E‐conjugated Antibody, Is a Potential Therapeutic Approach in Merkel Cell Carcinoma*.” British Journal of Dermatology, vol. 186, no. 2, Feb. 2022, pp. 295–306. EBSCOhost, https://doi.org/10.1111/bjd.20770.
APA
Esnault, C., Leblond, V., Martin, C., Desgranges, A., Baltus, C. B., Aubrey, N., Lakhrif, Z., Lajoie, L., Lantier, L., Clémenceau, B., Sarma, B., Schrama, J., Houben, R., Schrama, D., Hesbacher, S., Gouilleux, G. V., Feng, Y., Dimitrov, D., Guyétant, S., & Berthon, P. (2022). Adcitmer®, a new CD56‐targeting monomethyl auristatin E‐conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma*. British Journal of Dermatology, 186(2), 295–306. https://doi.org/10.1111/bjd.20770
Chicago
Esnault, C., V. Leblond, C. Martin, A. Desgranges, C.B. Baltus, N. Aubrey, Z. Lakhrif, et al. 2022. “Adcitmer®, a New CD56‐targeting Monomethyl Auristatin E‐conjugated Antibody, Is a Potential Therapeutic Approach in Merkel Cell Carcinoma*.” British Journal of Dermatology 186 (2): 295–306. doi:10.1111/bjd.20770.